Inhibikase Therapeutics, Inc. (IKT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.59-2.45%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Inhibikase Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	400,000
EPS	—	-0.115
Annual ending 2026-12-31
Revenue	—	285,714
EPS	—	-0.435
Annual ending 2027-12-31
Revenue	—	400,000
EPS	—	-0.459

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS loss narrows from -$0.37 in FY26	A supporting condition in Inhibikase Therapeutics, Inc.'s published investment case. The stated target is EPS loss improves or stays >= -$0.37 in FY26.	Intact	EPS loss worsens beyond -$0.37 in FY26	Diluted EPS: $-0.11 per share FY2026-Q2; GAAP. Published target: EPS loss improves or stays >= -$0.37 in FY26. Target period ends 2026-12-31; this observation covers 2026-Q2. Source published Aug 11, 2026-0.11 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ce4f6842-6ff4-4963-9be5-469c80dc7e22. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating losses do not worsen beyond $17.8 million in 2026-Q1	It aims to manage losses better.	Intact	Operating loss worsens beyond $17.8 million in 2026-Q1	Operating income: $-21.051M FY2026-Q2; GAAP. Published target: Operating loss <= $17.8 million in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 11, 2026-21,050,995 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ce4f6842-6ff4-4963-9be5-469c80dc7e22. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue grows above $250,000 in FY26	A primary condition in Inhibikase Therapeutics, Inc.'s published investment case. The stated target is Revenue >= $250,000 in FY26.	Intact	Revenue falls below $250,000 in FY26	Revenue: $0 FY2026-Q2; GAAP. Published target: Revenue >= $250,000 in FY26. Target period ends 2026-12-31; this observation covers 2026-Q2. Source published Aug 11, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.46

Unavailable → $-0.46 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$500,000	4 / 7
2026-07-25	Unavailable	$500,000	4 / 7
2026-07-26	Unavailable	$500,000	4 / 7
2026-07-27	Unavailable	$500,000	4 / 7
2026-07-28	Unavailable	$500,000	4 / 7
2026-07-29	Unavailable	$500,000	4 / 7
2026-07-30	Unavailable	$285,710	2 / 7
2026-07-31	Unavailable	$285,710	2 / 7
2026-08-01	Unavailable	$500,000	4 / 7
2026-08-02	Unavailable	$500,000	4 / 7
2026-08-03	Unavailable	$285,710	2 / 7
2026-08-04	Unavailable	$285,710	2 / 7
2026-08-05	Unavailable	$285,710	2 / 7
2026-08-06	Unavailable	$285,710	2 / 7
2026-08-07	Unavailable	$500,000	4 / 7
2026-08-08	Unavailable	$500,000	4 / 7
2026-08-09	Unavailable	$285,710	3 / 7
2026-08-10	Unavailable	$500,000	4 / 7
2026-08-12	Unavailable	$285,710	3 / 7
2026-08-13	Unavailable	$500,000	4 / 7
2026-08-14	Unavailable	$500,000	4 / 7
2026-08-15	$-0.45	$500,000	5 / 7
2026-08-16	$-0.45	$500,000	5 / 7
2026-08-17	$-0.45	$500,000	5 / 7
2026-08-18	$-0.45	$500,000	5 / 7
2026-08-19	$-0.45	$500,000	5 / 7
2026-08-20	$-0.47	$500,000	5 / 7
2026-08-21	$-0.47	$500,000	5 / 7
2026-08-22	$-0.47	$500,000	5 / 7
2026-08-23	$-0.47	$500,000	5 / 7
2026-08-24	$-0.47	$500,000	5 / 7
2026-08-25	$-0.47	$500,000	5 / 7
2026-08-26	$-0.47	$500,000	5 / 7
2026-08-27	$-0.47	$500,000	5 / 7
2026-08-28	$-0.47	$500,000	5 / 7
2026-08-29	$-0.47	$500,000	5 / 7
2026-08-30	$-0.47	$500,000	5 / 7
2026-08-31	$-0.47	$500,000	5 / 7
2026-09-01	$-0.47	$500,000	5 / 7
2026-09-02	$-0.47	$500,000	5 / 7
2026-09-03	$-0.47	$500,000	5 / 7
2026-09-04	$-0.47	$500,000	5 / 7
2026-09-05	$-0.47	$500,000	5 / 7
2026-09-06	$-0.47	$500,000	5 / 7
2026-09-07	$-0.47	$500,000	5 / 7
2026-09-08	$-0.47	$500,000	5 / 7
2026-09-09	$-0.47	$500,000	5 / 7
2026-09-10	$-0.47	$500,000	5 / 7
2026-09-11	$-0.47	$500,000	5 / 7
2026-09-12	$-0.47	$500,000	5 / 7
2026-09-13	$-0.47	$500,000	5 / 7
2026-09-14	$-0.47	$500,000	5 / 7
2026-09-15	$-0.47	$500,000	5 / 7
2026-09-16	$-0.47	$500,000	5 / 7
2026-09-17	$-0.47	$500,000	5 / 7
2026-09-18	$-0.47	$500,000	5 / 7
2026-09-19	$-0.47	$500,000	5 / 7
2026-09-20	$-0.47	$500,000	5 / 7
2026-09-21	$-0.47	$500,000	5 / 7
2026-09-22	$-0.47	$500,000	5 / 7
2026-09-23	$-0.47	$500,000	5 / 7
2026-09-24	$-0.47	$500,000	5 / 7
2026-09-25	$-0.47	$500,000	5 / 7
2026-09-26	$-0.47	$500,000	5 / 7
2026-09-27	$-0.47	$500,000	5 / 7
2026-09-28	$-0.47	$500,000	5 / 7
2026-09-29	$-0.47	$500,000	5 / 7
2026-09-30	$-0.47	$500,000	5 / 7
2026-10-01	$-0.47	$500,000	5 / 7
2026-10-02	$-0.47	$500,000	5 / 7
2026-10-03	$-0.47	$500,000	5 / 7
2026-10-04	$-0.47	$500,000	5 / 7
2026-10-05	$-0.47	$500,000	5 / 7
2026-10-06	$-0.47	$500,000	5 / 7
2026-10-07	$-0.47	$500,000	5 / 7
2026-10-08	$-0.47	$500,000	5 / 7
2026-10-09	$-0.47	$500,000	5 / 7
2026-10-10	$-0.47	$500,000	5 / 7
2026-10-11	$-0.47	$500,000	5 / 7
2026-10-12	$-0.47	$500,000	5 / 7
2026-10-13	$-0.47	$500,000	5 / 7
2026-10-14	$-0.46	$400,000	5 / 7
2026-10-15	$-0.46	$400,000	6 / 7
2026-10-16	$-0.46	$400,000	6 / 8
2026-10-17	$-0.46	$400,000	6 / 8
2026-10-18	$-0.46	$400,000	6 / 8
2026-10-19	$-0.46	$400,000	6 / 8
2026-10-20	$-0.46	$400,000	6 / 8
2026-10-21	$-0.46	$400,000	6 / 8
2026-10-22	$-0.46	$400,000	6 / 8
2026-10-23	$-0.46	$400,000	6 / 8
2026-10-24	$-0.46	$400,000	6 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	0
2026-06-01	8	0
2026-07-01	9	0
2026-08-01	9	0
2026-09-01	9	0
2026-10-01	9	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Chardan CapitalOct 13

$1.50New observation · no comparable prior

$0$0.83$1.65

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS loss narrows from -$0.37 in FY26Diluted EPS: $-0.11 per share
Operating losses do not worsen beyond $17.8 million in 2026-Q1Operating income: $-21.051M
Revenue grows above $250,000 in FY26Revenue: $0

Next proof point

Nov 13, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-36.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Inhibikase Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative healthcare growth, not an established compounder: IKT is loss-making, recent financial performance is weak, and risk is elevated. The long-term thesis is on watch, with the muted recent reaction not removing the gap between its results and the industry cohort.

What's priced into Inhibikase Therapeutics, Inc.

IKT carries a valuation premium versus peers, but confidence in that comparison is low and the premium is linked to potential future opportunity. The evidence does not show that the market has priced in a specific clinical outcome or earnings path, so expectations are difficult to judge precisely.

What the fundamentals likely do

Over the multi-year view, progress depends on advancing the Phase 3 IMPROVE-PAH study of IKT-001 and using its Orphan Drug Designation; both remain watch items. Near term, losses and cash runway remain concerns, while consecutive earnings misses and elevated miss risk leave execution vulnerable. Recent filings include a director transition, a change in certifying accountant, and unregistered equity sales.

What Inhibikase Therapeutics, Inc. hinges on

The favorable case depends on clinical and development progress, disciplined management of operating losses, and supportive healthcare-sector momentum. The unfavorable case includes another guidance cut or further weakening in jobs data, which could add pressure to cyclical healthcare names. The evidence does not establish how these scenarios would affect IKT's longer-term prospects.